Abstract
Background
Disseminated intravascular coagulation (DIC) occurs in several clinical conditions, including drug therapy. We aim to investigate the association between the administration of several drug classes and the onset of DIC by using the reports of Adverse Drug Reactions (ADR) collected in Vigibase, the World Health Organization (WHO) database of ADR.
Methods
We collected reports of drug-related DIC from 1968 to September 2015, classified in Vigibase according to the MedDRA (Medical Dictionary for Regulatory Activities) term “Disseminated intravascular coagulation”. A disproportionality analysis using Reporting Odds Ratio (ROR) with 95% Confidence Interval (CI95%) was performed.
Results
Overall, 4653 reports of drug-associated DIC were retrieved and the 75.9% of them was serious according to WHO seriousness criteria. DIC was significantly (ROR > 1, lower limit of CI95% > 1) associated with 88 drugs, mainly antineoplastic agents, antithrombotic agents and antibacterials for systemic use. Among of the most frequently reported individual drugs we found dabigatran (94 reports) ROR = 1.34 (CI95% 1.08–1.67), oxaliplatin and bevacizumab both with 75 reports and ROR = 1.77 (1.38–2.27) and 2.02 (1.57–2.61), respectively.
Conclusion
A substantial number of drugs, widely used in the clinical practice, may be associated with the potential occurrence of DIC. For many of these drugs, the ADR is not acknowledged in the corresponding Summary of Product Characteristics. The high number of drugs involved underlines the importance of evaluate this condition such as an ADR that might occur during drug therapy.
Similar content being viewed by others
References
Brunton L, Chabner BA, Knollman B (2012) Goodman & Gilman's the pharmacological basis of therapeutics, 12th edn. McGraw-Hill Education/Medical, New York
Gando S, Otomo Y (2015) Local hemostasis, immunothrombosis, and systemic disseminated intravascular coagulation in trauma and traumatic shock. Crit Care. https://doi.org/10.1186/s13054-015-0735-x
Wada H, Matsumoto T, Yamashita Y (2014) Diagnosis and treatment of disseminated intravascular coagulation (DIC) according to four DIC guidelines. J Intensive Care. https://doi.org/10.1186/2052-0492-2-15
Levi M, Ten Cate H (1999) Disseminated Intravascular Coagulation. N Engl J Med. https://doi.org/10.1056/NEJM199908193410807
Liles NW, Page EE, Liles AL et al (2016) Diversity and severity of adverse reactions to quinine: a systematic review. Am J Hematol. https://doi.org/10.1002/ajh.24314
White SR (2002) Amphetamine toxicity. Semin Respir Crit Care Med. https://doi.org/10.1055/s-2002-20586
The WHO Programme for International Drug Monitoring. https://www.who.int/medicines/areas/quality_safety/safety_efficacy/National_PV_Centres_Map/en/. Accessed 22 Nov 2019
European Medicine Agency (2017) Guideline on good pharmacovigilance practices (GVP). https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf
Brown EG, Wood L, Wood S (1999) Drug-safety 20:109. https://doi.org/10.2165/00002018-199920020-00002
Monaco L, Biagi C, Conti V et al (2017) Safety profile of the direct oral anticoagulants: an analysis of WHO database of adverse drug reactions. Br J Clin Pharmacol. https://doi.org/10.1111/bcp.13234
Shibata A, Hauben M (2011) Pharmacovigilance, signal detection and signal intelligence overview. In Information fusion (FUSION). In: Proceedings of the 14th international conference, Chicago, IL, USA, July 5–8 2011. IEEE, New York, NY, pp 1–7
Italian Medicine Agency (2016) Report. https://www.agenziafarmaco.gov.it/wscs_render_attachment_by_id/111.28397.11666135094017ecc.pdf. Accessed 22/01/2018
Clark R, Borirakchanyavat V, Gazzard BG et al (1973) Disorderd hemostasis in liver damage from paracetamol overdose. Gastroenterology 65(5):788–795
Mizota A, Shitara K, Kondo C et al (2011) A case of heavily pretreated rectal cancer with disseminated intravascular coagulation that improved following reintroduction of FOLFOX plus bevacizumab. Int J Clin Oncol. https://doi.org/10.1007/s10147-011-0242-2
Waddle M, Irvin M, Gupta E et al (2017) Acute disseminated intravascular coagulation after oxaliplatin infusion. Chemotherapy 62(5):295–300. https://doi.org/10.1159/000471844
Marler J, Usery JB, Nolan S et al (2016) antithrombotic usage patterns in the era of new oral anticoagulant options for atrial fibrillation. Hosp Pharm 51(7):564–571. https://doi.org/10.1310/hpj5107-564
Staerk L, Fosbøl EL, Gadsbøll K et al (2016) Non-vitamin K antagonist oral anticoagulation usage according to age among patients with atrial fibrillation: temporal trends 2011–2015 in Denmark. Sci Rep 6:31477. https://doi.org/10.1038/srep31477
Piedra Abusharar S, Shah N, Patel R et al (2019) A case of confirmed ceftriaxone-induced immune thrombocytopenia. Cureus 11(5):e4688. https://doi.org/10.7759/cureus.4688
Biagi C, Montanaro N, Buccellato E et al (2013) Underreporting in pharmacovigilance: an intervention for Italian GPs (Emilia–Romagna region). Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-012-1321-7
Acknowledgements
We are grateful to the Uppsala Monitoring Centre—WHO Collaborating Centre for International Drug Monitoring for providing data. The information comes from a variety of sources, and the likelihood that the suspected adverse reaction is drug-related is not the same in all cases. The information does not represent the opinion of the World Health Organization. We would like to thank Mauro Venegoni, MD, for his authoritative and helpful comments to the manuscript and Laura Rossi, PharmD, who participated in this research when preparing her graduation thesis at the Unit of Pharmacology, University of Bologna.
Author information
Authors and Affiliations
Contributions
Conceptualization, GB, AV and DM; Data curation, MM; Formal analysis, GB, AV, MM, DM; Investigation, GB, DM; Methodology, GB, DM, MM; Supervision, AV; Validation, MM; Writing—original draft, GB, DM; Writing—review & editing, GB, AV, MM, DM.
Corresponding author
Ethics declarations
Conflict of interest
All the Authors declare that they have no conflict of interest. This manuscript has no founding source.
Informed consent
The manuscript does not contain clinical studies or patient data. For this type of study, formal consent is not required.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Bonaldo, G., Vaccheri, A., Melis, M. et al. Drug-induced disseminated intravascular coagulation: a pharmacovigilance study on World Health Organization’s database. J Thromb Thrombolysis 50, 763–771 (2020). https://doi.org/10.1007/s11239-020-02147-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11239-020-02147-y